Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-200 in advanced solid tumors
NCT03953742Phase 1Completed
- Sponsor
- Coordination Pharmaceuticals, Inc.
- Start
- Jul 2019
- Primary completion
- Feb 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CPI-200 in solid tumor (advanced stage), sponsored by Coordination Pharmaceuticals, Inc. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Jul 2019; status: completed.
02
Drugs
CPI-200
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03953742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953742.